All In Biotech

Drug Trial Radar · NCT03405818

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months

Last checked: Nov 20, 2026Latest source record: Apr 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Oct 22, 2015

Primary completion

Jul 27, 2017

Study completion Jul 27, 2017

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 72 months, up to 203 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (a fungal infection) of the toenail in children and adolescents (ages 6 to 16 years). Following confirmation of eligibility, including laboratory evidence of a fungal organism in the toenail, tavaborole topical solution was applied once daily to all affected toenails for a 48-week treatment period. Clinical assessment of the extent of infection and safety assessments were performed periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after stopping the treatment). A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small area of surrounding skin during the first 28 days. These subjects had blood samples analyzed to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical solution in children and adolescents.

Conditions

  • Onychomycosis
  • Tinea Unguium

Interventions

  • Tavaborole 5% Topical SolutionDrug

    topical solution for application to toenails

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Local Tolerability Reactions by SeverityTime frame: Baseline up to Week 52
  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 28 days after last dose of study drug (up to Week 52)
  3. Number of Participants With Adverse Events (AEs) By SeverityTime frame: Baseline up to 28 days after last dose of study drug (up to Week 52)
  4. Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 24Time frame: Baseline, Week 24
  5. Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 52Time frame: Baseline, Week 52
  6. Change From Baseline in Hematology Parameter (Hematocrit) at Week 24Time frame: Baseline, Week 24
  7. Change From Baseline in Hematology Parameter (Hematocrit) at Week 52Time frame: Baseline, Week 52
  8. Change From Baseline in Hematology Parameter (Erythrocytes) at Week 24Time frame: Baseline, Week 24
  9. Change From Baseline in Hematology Parameter (Erythrocytes) at Week 52Time frame: Baseline, Week 52
  10. Change From Baseline in Hematology Parameters (Hemoglobin) at Week 24Time frame: Baseline, Week 24
  11. Change From Baseline in Hematology Parameters (Hemoglobin) at Week 52Time frame: Baseline, Week 52
  12. Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 24Time frame: Baseline, Week 24
  13. Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 52Time frame: Baseline, Week 52
  14. Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 24Time frame: Baseline, Week 24
  15. Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 52Time frame: Baseline, Week 52
  16. Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 24Time frame: Baseline, Week 24
  17. Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 52Time frame: Baseline, Week 52
  18. Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 24Time frame: Baseline, Week 24
  19. Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 52Time frame: Baseline, Week 52
  20. Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 24Time frame: Baseline, Week 24
  21. Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 52Time frame: Baseline, Week 52
  22. Change From Baseline in Vital Sign (Blood Pressure) at Week 24Time frame: Baseline, Week 24
  23. Change From Baseline in Vital Sign (Blood Pressure) at Week 52Time frame: Baseline, Week 52
  24. Change From Baseline in Vital Sign (Pulse Rate) at Week 24Time frame: Baseline, Week 24
  25. Change From Baseline in Vital Sign (Pulse Rate) at Week 52Time frame: Baseline, Week 52
  26. Change From Baseline in Vital Sign (Respiratory Rate) at Week 24Time frame: Baseline, Week 24
  27. Change From Baseline in Vital Sign (Respiratory Rate) at Week 52Time frame: Baseline, Week 52
  28. Percentage of Participants With Complete Cure of Target Great Toenail (TGT) at Week 52Time frame: Week 52

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Madera Family Medical Group

    Madera, California

  • Stanford University School of Medicine

    Palo Alto, California

  • MedStar Health Research Institute - MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Doctors Research Network

    South Miami, Florida

  • University Hospital, SUNY Downstate Medical Center

    Brooklyn, New York

  • Skin Specialty Dermatology

    New York, New York

  • Cyn3rgy Research

    Gresham, Oregon

  • Oregon Dermatology & Research Center

    Portland, Oregon

  • West Houston Clinical Research Services LLC

    Houston, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Jordan Valley Dermatology Center

    West Jordan, Utah

  • PI Coor Clinical Research, LLC

    Burke, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.